Genmab — April 2016
-
hvot darxalex på 19.7 var trukket fra
-
Other oncology var 49m i Q4 (incl Darzalex)
-
Ja så Darzalex er nok et sted mellem 105 og 115 ? realistisk set
-
MUFC havde du ikke 30 i jan og 38 i feb inkl.off label, det skrev du i går
-
ja mobbyduck. Men det er jo lidt gætværk hvor meget der ligger uden for institutional sales. Nogen siger 15% nogen siger 20%!
-
ja de 38 i feb er inkl 15%,
-
Other oncology sales: Q4 14 15m, Q1 15 15m, Q2 15 18m, Q3 15 20m, Q4 15 49m, Q1 16 145m
-
Så indtil Darzalex er med, er der meget beskeden vækst fra kvartal til kvartal
-
keep dreaming!
-
JnJ opjusterer faktisk https://www.nordnet.dk/mux/web/analys/nyheter/visaNyhet.html?itemid=388183013&sourcecode=ddk
-
J&J's pharmaceutical business, the company's largest, grew 5.9% to $8.18 billion, lifted by a 12.9% increase in U.S. pharmaceutical sales. Strong sales of the diabetes drug Invokana, blood-cancer drug Imbruvica, blood-thinner Xarelto and multiple myeloma drug Darzalex, offset lower sales of the hepatitis drug Olysio, which is facing increased competition.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind